Chile’s Covid‑19 Vaccine Quest: One Shot Magic
On April 7, Chile’s health regulator gave the green light to emergency use of the single‑dose Covid‑19 shot from CanSino, a Chinese biotech firm. The decision comes as the country dives into a massive vaccination push while grappling with a second wave of infections.
Why a One‑Dose Wonder?
- The CanSino vaccine is only a single injection – perfect for reaching Chile’s remote communities that might struggle to get people for a two‑dose schedule.
- Already approved in China, Mexico, Pakistan, and Hungary, it’s slated for arrival between May and June.
- President Sebastian Pinera announced in late March that the government would purchase 1.8 million vials.
Other Players in the Race
Johnson & Johnson’s single‑dose jab also ran through trials in Chile, but a promised supply deal fell through. Global demand from the United States and Europe snatched up its quota, leaving Chile scrambling for alternatives.
The Approval Crunch
The Institute of Public Health voted 10‑2‑1 (10 for, 2 against, 1 abstention) to roll out CanSino for people up to 60 years old. Here’s what the numbers look like so far:
- 7.1 million first doses (Sinovac or Pfizer‑BioNTech)
- 4.2 million second doses
- Goal: 9 million people with at least one dose by May 9
- Target: 80 % coverage of the eligible population by July
Why the Surge?
South America’s worst outbreak yet is hitting a peak of over 8,000 new cases. Health experts point fingers at:
- The end of the southern‑hemisphere summer holidays
- Returned crowds in work, schools, and public transport
- Weaker self‑care and movement restrictions
Chile’s Bigger Picture
It’s a race against time and the virus. By bringing a single‑dose, easy‑to‑administer vaccine into the mix, Chile hopes to streamline vaccination logistics and get the hard‑to‑reach folks in the line faster.
Stay tuned – as Chile rolls out CanSino, the next chapter in the fight against Covid‑19 is just a shot away.
